$58.85
0.94% yesterday
Nasdaq, Sep 27, 09:44 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Stock price

$58.78
-4.47 7.07% 1M
-10.91 15.66% 6M
+3.64 6.60% YTD
-1.45 2.41% 1Y
+26.92 84.49% 3Y
-13.59 18.78% 5Y
+30.24 105.96% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.48 0.82%
ISIN
US00182C1036
Symbol
ANIP
Sector
Industry

Key metrics

Market capitalization $1.23b
Enterprise Value $1.29b
P/E (TTM) P/E ratio 47.67
EV/FCF (TTM) EV/FCF 12.96
EV/Sales (TTM) EV/Sales 2.39
P/S ratio (TTM) P/S ratio 2.28
P/B ratio (TTM) P/B ratio 2.70
Revenue growth (TTM) Revenue growth 34.27%
Revenue (TTM) Revenue $538.95m
EBIT (operating result TTM) EBIT $44.69m
Free Cash Flow (TTM) Free Cash Flow $99.54m
Cash position $247.05m
EPS (TTM) EPS $1.22
P/E forward 49.83
P/S forward 2.08
EV/Sales forward 2.18
Short interest 13.69%
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
80%
Hold
20%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
539 539
34% 34%
100%
- Direct Costs 268 268
29% 29%
50%
271 271
39% 39%
50%
- Selling and Administrative Expenses 127 127
60% 60%
24%
- Research and Development Expense 39 39
48% 48%
7%
105 105
19% 19%
20%
- Depreciation and Amortization 61 61
2% 2%
11%
EBIT (Operating Income) EBIT 45 45
52% 52%
8%
Net Profit 25 25
589% 589%
5%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI's Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Niz...
Neutral
GlobeNewsWire
11 days ago
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”).
Neutral
GlobeNewsWire
12 days ago
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM).
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 642
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today